

1 of 36

T C T E E D D " D S S E H G G D




FIG. 1

TYPE III "SAGE" 1660




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

Experimental Protocol

5TGM1




Figure 7

Serum IgG₂ levels in 5TGM1-bearing mice




Figure 8

Tumor Volume in Bone

Treatment/no treatment (%)
n=6-12




Figure 9

EFFECT OF PS/2 mAb TREATMENT
ON SPLEEN WEIGHT




Figure 10

EFFECT OF PS/2 TREATMENT ON SPLENOCYTES
IN MICE WITH 5TGM1 MYELOMA





Figure 11

EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE


DISEASE FREE



File: do111700.077 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9624
 Total Events: 10707 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	9499	98.70	88.72	37.11	1120.67
UR	3	0.03	0.03	5084.96	773.52
LL	122	1.27	1.14	31.88	11.09
LR	0	0.00	0.00	***	***


UNTREATED



File: do111700.100 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9526
 Total Events: 11100 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4959	52.06	44.68	84.30	1023.41
UR	1388	14.57	12.50	2377.81	704.20
LL	2163	22.71	19.49	50.53	6.64
LR	1016	10.67	9.15	3619.03	4.05


PS/2 TREATED



File: do111700.120 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9561
 Total Events: 10934 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	7868	82.29	71.96	58.00	1139.33
UR	310	3.24	2.84	1922.82	897.47
LL	1171	12.25	10.71	42.10	8.17
LR	212	2.22	1.94	3153.17	3.62

rat IgG2b TREATED



File: do111700.137 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9595
 Total Events: 10970 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4910	51.17	44.76	84.95	975.19
UR	1384	14.42	12.62	1937.36	694.49
LL	1704	17.76	15.53	48.67	7.00
LR	1597	16.64	14.56	3286.15	2.68

Figure 12

EFFECT OF PS/2 mAb TREATMENT ON
SPEEN TUMOR BURDEN




Figure 13

T C T E 2 0 " 6 5 9 G H 6 6 0

EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS
IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN
mIgG2b POSITIVE CELLS




Figure 15

TCFEG "GAGE" GCG

EFFECT OF PS/2 mAb TREATMENT
ON 5TGM1 CELLS IN THE BLOOD




Figure 16

EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

TELEGE 659660

EFFECT OF PS/2 mAb ON
CIRCULATION mlgG2b LEVELS




Figure 18

C57Bl/KaLwRaj MULTIPLE MYELOMA MODEL
ACUTE TREATMENT PROTOCOLS




Figure 19

EFFECT OF PS/2 TREATMENT ON IgG2b POSITIVE CELLS
ACUTE TREATMENT MODEL




Figure 20

EFFECT OF ANTI VLA-4 ANTIBODY PS/2
ON TUMOR BURDEN IN SPLEEN




Figure 21

EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

EFFECT OF 6 DAYS OFF PS/2 TREATMENT ON BONE MARROW CELLS





Figure 23

C57/BLK_aLwRaj MODEL OF MULTIPLE MYELOMA
COMBINATION TREATMENT WITH PS/2 AND MELPAHLAN



5TGMI CELLS (10⁶) WERE INJECTED (I.V.) ON DAY 0
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27

GROUPS N=3/GROUP

DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
MELPAHLAN TREATMENT -- 100 MICROGRAMS/INJECTION
PS/2 TREATMENT -- 100 MICROGRAMS/INJECTION
MELPAHLAN AND PS/2
MELPAHLAN AND rIgG2b ISOTYPE CONTROL

Figure 24

EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27




Figure 26

EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27





Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detect d	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 µg/ml	none detected
13-melphalan+PS/2	none detected	none detected

卷之三

Figure 28

C57/B1K_aLwRaj MODEL OF MULTIPLE MYELOMA
PS/2 AND ANTI VLA4 SMALL MOLECULE
LONG TERM TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP
DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
PS/2 -- 100 micrograms/injection
Sm. Mol . 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
Sm. Mol. 9257 CONTROL -- 3 mg/kg

Figure 29

EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN

FOURTEEN 659E41660





Figure 31

T D F E 20 " S S E 4 6 6 0

C57/B1K wRaj MODEL OF MULTIPLE MYELOMA
PS/2 AND ANTI VLA4 SMALL MOLECULE
ACUTE TREATMENT



STGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0
PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20
SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP
DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
PS/2 --100 micrograms/injection
8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
9257 CONTROL -- 3 mg/kg

Figure 32

F0TE30"659241560





Figure 33

EFFECT OF ACUTE TREATMENT ON TUMOR BURDEN

SPLEEN



BONE MARROW




Figure 34

FOT 230 294 660

Experimental Protocol




Figure 35

Inhibition of Hindleg Paralysis




Figure 36